Navigation Links
Non-wovens as scaffolds for artificial tissue
Date:5/13/2009

This release is available in German.

When someone's knee hurts with every step it's a sign that the cartilage has been so badly damaged that the bones rub together when walking. Medical scientists are developing a technique to produce cartilage tissue artificially so that patients with such knee problems can walk free of pain again. The aim is also to make tendons and blood vessels in the laboratory. The research scientists place cells on a porous scaffold material, for example a non-woven made of polymer fibers. The cells can then grow on this frame and form tissue. Whether the cells will grow properly into tissue, however, depends on many factors. For instance, the cells only form cartilage if they are subjected to loads comparable with those in the body. To form cartilage the tissue needs to experience the pressure applied by every step. By contrast, blood vessel tissue needs the pulsation of the blood. The scientists reproduce these loads in the cell culture. When the artificial cartilage is inserted in the patient's knee the supporting scaffold is gradually resorbed and only the cartilage tissue remains.

While it is quite easy to produce npn-wovens from thin polymer fibers, it is difficult to describe these materials experimentally and theoretically. What forces do the cells experience when the non-woven is pulled or when a liquid passes through the fibre network? How do cells penetrate the non-woven? How do liquids permeate the non-woven? Research scientists at the Fraunhofer Institute for Mechanics of Materials IWM in Freiburg and Halle have developed a simulation model which answers these questions and characterizes the fleeces. "The simulation reproduces the mechanical properties of the fleeces and the transport processes the software can therefore also calculate how nutrients are transported to the cells and metabolic products are tr
'/>"/>

Contact: Dr. Raimund Jaeger
raimund.jaeger@iwm.fraunhofer.de
49-761-514-2284
Fraunhofer-Gesellschaft
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Smart scaffolds may help heal broken hearts
2. Development of an artificial simulator of the nervous system to do research into diseases
3. Red pandas reveal an unexpected (artificial) sweet tooth
4. Artificial cells, simple model for complex structure
5. TECNALIA uses artificial vision to improve recycling of electronic scrap metal
6. Biomedical researchers create artificial human bone marrow in a test tube
7. Scientists identify cell changes leading to impaired artificial kidney function
8. Evolved Machines Selected as a Prime Contractor for DARPA Program to Engineer an Artificial Olfaction System
9. Researchers design artificial cells that could power medical implants
10. Taking the next step toward advanced artificial limbs
11. Complex ocean behavior studied with artificial upwelling
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Non-wovens as scaffolds for artificial tissue
Non-wovens as scaffolds for artificial tissue
Breaking Biology News(10 mins):MSU researcher unveils new approach to treat lower back pain 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10Plate-eating good: Université de Montréal professor designs edible tableware 2Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13924 1Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13924 2VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 1VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 2VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 3VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 4VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 5VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 6VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 7VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 8VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 9New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary Helsinn Therapeutics 28U S 29 In 56516 1New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary Helsinn Therapeutics 28U S 29 In 56516 2